The Pulse
Oracle releases clinical trial AI agents to early adopters
Oracle’s new Life Sciences AI Agents are available to early adopters for trial monitoring, planning and conduct. People must review recommendations and approve proposed actions before execution.

Early adopters can now use Oracle Life Sciences AI Agents to monitor and plan clinical trials and support trial conduct. Oracle said the agents are designed to identify operational issues, recommend actions and coordinate responses using information from its life sciences applications and supported third-party sources.
Source webwire.com
People are responsible for reviewing the recommendations and approving proposed actions before they are carried out. The product was introduced on November 18.
Monitoring studies
The agents are designed to bring together information from applications used in clinical development. Oracle’s user guide lists possible source applications including Clinical One Cloud Service and a Clinical Trial Management System. It also lists Site Activate, Site Select and Electronic Trial Master File.
The system is intended to give clinical operations leads and executives a view of portfolio health across studies, sites and countries, according to the guide. Agents highlight emerging risks involving enrollment, timelines or quality metrics, with alerts and suggested actions.
In one example from the announcement, an agent can monitor study performance and likely drivers of deviations from key performance indicators. It can also recommend operational actions that follow the trial protocol.
Planning and startup
For trial planning and startup, study managers and clinical operations leads can generate plans from protocol inputs, the user guide says. The AI extracts key parameters and can model timelines and budgets. The planning tools can also rank countries and sites and initiate activation workflows.
The product brings processes from separate Oracle Life Sciences applications into a shared workspace for trial oversight and decision-making. Its initial focus covers portfolio monitoring as well as planning and conduct, while the agents’ proposed actions remain subject to human review and approval.
Data and future work
The product aggregates data from connected source systems and applies standard analytics and rule-based logic to surface operational insights. The guide says it does not use a proprietary algorithm to calculate clinical data. AI-driven suggestions use non-proprietary reasoning patterns and do not alter or calculate clinical measurements.
Oracle plans enhancements intended to extend the AI-assisted capabilities beyond the areas covered for early adopters. The planned areas include clinical data management, post-trial analytics, trial design and post-market workflows.
Seema Verma, executive vice president and general manager of Oracle Health and Life Sciences, said clinical development requires coordination across studies, applications, data and teams. The agents are intended to support that work across clinical development workflows.
Sources
Related stories
- Microsoft introduces enterprise policy controls for AI agents
- Meta says AI agents handle most ads-ranking technique transfers
- Mitsubishi Electric adopts Salesforce AI agents under global deal
- FlowForma launches AI agent monitoring and control hub
- Google opens global waitlist for experimental Stitch Loop agent